The University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) has declared a critical incident due to high demand ...

The University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) has declared a critical incident affecting all ...

The University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) has declared a critical incident affecting all ...

Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory ...

Across conversations on precision oncology, malignant hematology, cellular therapies, and social determinants of health (SDOH ...

Two University of Bristol scientists have been awarded over £2 million to work with US researchers on pioneering Quantum Information Science projects unlocking new approaches in drug design, solar ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

Deucravacitinib reduces circulating proteins associated with kidney dysfunction in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2025.“Specific plasma ...

Patients with uveal melanoma may respond to T-cell therapy directed at an antigen that is highly expressed in the tumors, ...

In this video, Leo I. Gordon, MD, FACP, discusses notable presentations from Lymphoma, Leukemia & Myeloma Congress.

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

CHICAGO -- Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in ...